A novel anti-melanoma SRC-family kinase inhibitor

The major drawback of melanoma therapy with BRAF and MAPK inhibitors is the innate and acquired drug resistance. We therefore explored alternative targets and developed a new compound, SAB298, that is a SRC-family kinase (SFK) inhibitor. The drug is cytotoxic to patient-derived melanoma cells regard...

Descripción completa

Detalles Bibliográficos
Autores principales: Halaban, Ruth, Bacchiocchi, Antonella, Straub, Robert, Cao, Jian, Sznol, Mario, Narayan, Deepak, Allam, Ahmed, Krauthammer, Michael, Mansour, Tarek S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481345/
https://www.ncbi.nlm.nih.gov/pubmed/31040916
http://dx.doi.org/10.18632/oncotarget.26787

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481345/
https://www.ncbi.nlm.nih.gov/pubmed/31040916
http://dx.doi.org/10.18632/oncotarget.26787

Ejemplares similares